S&P 500   3,116.39 (-0.38%)
DOW   26,957.59 (-0.46%)
QQQ   216.48 (+0.52%)
AAPL   292.65 (+1.59%)
FB   197.20 (+0.22%)
MSFT   170.17 (+1.25%)
GOOGL   1,390.47 (+0.30%)
AMZN   1,979.59 (+0.35%)
CGC   19.82 (+1.02%)
NVDA   267.65 (+2.14%)
BABA   208.74 (+1.52%)
MU   52.37 (+0.52%)
GE   10.95 (-3.27%)
TSLA   778.80 (-2.64%)
AMD   47.49 (-0.17%)
T   37.10 (-0.67%)
ACB   1.51 (+0.00%)
F   7.21 (-0.28%)
NFLX   379.24 (+5.32%)
PRI   120.14 (-1.05%)
BAC   30.63 (-1.45%)
DIS   123.36 (-3.77%)
GILD   74.70 (+6.56%)
S&P 500   3,116.39 (-0.38%)
DOW   26,957.59 (-0.46%)
QQQ   216.48 (+0.52%)
AAPL   292.65 (+1.59%)
FB   197.20 (+0.22%)
MSFT   170.17 (+1.25%)
GOOGL   1,390.47 (+0.30%)
AMZN   1,979.59 (+0.35%)
CGC   19.82 (+1.02%)
NVDA   267.65 (+2.14%)
BABA   208.74 (+1.52%)
MU   52.37 (+0.52%)
GE   10.95 (-3.27%)
TSLA   778.80 (-2.64%)
AMD   47.49 (-0.17%)
T   37.10 (-0.67%)
ACB   1.51 (+0.00%)
F   7.21 (-0.28%)
NFLX   379.24 (+5.32%)
PRI   120.14 (-1.05%)
BAC   30.63 (-1.45%)
DIS   123.36 (-3.77%)
GILD   74.70 (+6.56%)
S&P 500   3,116.39 (-0.38%)
DOW   26,957.59 (-0.46%)
QQQ   216.48 (+0.52%)
AAPL   292.65 (+1.59%)
FB   197.20 (+0.22%)
MSFT   170.17 (+1.25%)
GOOGL   1,390.47 (+0.30%)
AMZN   1,979.59 (+0.35%)
CGC   19.82 (+1.02%)
NVDA   267.65 (+2.14%)
BABA   208.74 (+1.52%)
MU   52.37 (+0.52%)
GE   10.95 (-3.27%)
TSLA   778.80 (-2.64%)
AMD   47.49 (-0.17%)
T   37.10 (-0.67%)
ACB   1.51 (+0.00%)
F   7.21 (-0.28%)
NFLX   379.24 (+5.32%)
PRI   120.14 (-1.05%)
BAC   30.63 (-1.45%)
DIS   123.36 (-3.77%)
GILD   74.70 (+6.56%)
S&P 500   3,116.39 (-0.38%)
DOW   26,957.59 (-0.46%)
QQQ   216.48 (+0.52%)
AAPL   292.65 (+1.59%)
FB   197.20 (+0.22%)
MSFT   170.17 (+1.25%)
GOOGL   1,390.47 (+0.30%)
AMZN   1,979.59 (+0.35%)
CGC   19.82 (+1.02%)
NVDA   267.65 (+2.14%)
BABA   208.74 (+1.52%)
MU   52.37 (+0.52%)
GE   10.95 (-3.27%)
TSLA   778.80 (-2.64%)
AMD   47.49 (-0.17%)
T   37.10 (-0.67%)
ACB   1.51 (+0.00%)
F   7.21 (-0.28%)
NFLX   379.24 (+5.32%)
PRI   120.14 (-1.05%)
BAC   30.63 (-1.45%)
DIS   123.36 (-3.77%)
GILD   74.70 (+6.56%)
Log in

Alder Biopharmaceuticals News Headlines (NASDAQ:ALDR)

$18.88
0.00 (0.00 %)
(As of 10/22/2019)
Today's Range
$18.88
Now: $18.88
$18.88
50-Day Range
$18.88
MA: $18.88
$18.88
52-Week Range
$8.39
Now: $18.88
$19.12
VolumeN/A
Average Volume5.12 million shs
Market Capitalization$1.58 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.64

Headlines

Alder Biopharmaceuticals (NASDAQ ALDR) News Headlines

Source:
DateHeadline
Alder BioPharmaceuticals, Inc. Announces Closing of Public Offering and Private Placement of Common Stock and Exercise in FullAlder BioPharmaceuticals, Inc. Announces Closing of Public Offering and Private Placement of Common Stock and Exercise in Full
www.bloomberg.com - February 14 at 10:36 PM
Accesso Technology Finance Head John Alder To Step DownAccesso Technology Finance Head John Alder To Step Down
www.lse.co.uk - February 7 at 12:01 AM
Azelby out as CEO of Alder BioPharmaceuticals following close of $2B acquisitionAzelby out as CEO of Alder BioPharmaceuticals following close of $2B acquisition
finance.yahoo.com - December 5 at 11:45 PM
Did Hedge Funds Drop The Ball On On Alder Biopharmaceuticals Inc (ALDR) ?Did Hedge Funds Drop The Ball On On Alder Biopharmaceuticals Inc (ALDR) ?
finance.yahoo.com - October 28 at 11:05 PM
All You Need to Know About Alder BioPharmaceuticals (ALDR) Rating Upgrade to Strong BuyAll You Need to Know About Alder BioPharmaceuticals (ALDR) Rating Upgrade to Strong Buy
finance.yahoo.com - October 15 at 12:04 PM
Alder BioPharmaceuticals® Announces First-in-Human Dosing in Phase 1 ALD1910 Study for Preventive Treatment of MigraineAlder BioPharmaceuticals® Announces First-in-Human Dosing in Phase 1 ALD1910 Study for Preventive Treatment of Migraine
finance.yahoo.com - October 10 at 9:31 AM
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Alder BioPharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmINVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Alder BioPharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
finance.yahoo.com - October 1 at 8:26 PM
Use Rising P/E Strategy to Grab 5 Winning StocksUse Rising P/E Strategy to Grab 5 Winning Stocks
finance.yahoo.com - September 26 at 8:50 AM
Are Alder Shareholders Getting Enough in the Buyout?Are Alder Shareholders Getting Enough in the Buyout?
247wallst.com - September 16 at 11:20 AM
Alder Bio up 81% premarket on Lundbeck bidAlder Bio up 81% premarket on Lundbeck bid
seekingalpha.com - September 16 at 11:20 AM
Danish Company To Buy Migraine Drug Developer Alder Biopharma In Deal Worth Up To $1.95BDanish Company To Buy Migraine Drug Developer Alder Biopharma In Deal Worth Up To $1.95B
www.benzinga.com - September 16 at 11:20 AM
Alder Biopharmaceuticals Surges on Lundbeck OfferAlder Biopharmaceuticals Surges on Lundbeck Offer
www.thestreet.com - September 16 at 11:20 AM
Lundbeck to acquire Alder BioPharmaceuticals – a company committed to transforming migraine treatment and prevention – in a transaction valued at up to USD 1.95 billion net of cashLundbeck to acquire Alder BioPharmaceuticals – a company committed to transforming migraine treatment and prevention – in a transaction valued at up to USD 1.95 billion net of cash
finance.yahoo.com - September 16 at 11:20 AM
Lundbeck to buy migraine treatment developer Alder BioPharmaceuticalsLundbeck to buy migraine treatment developer Alder BioPharmaceuticals
finance.yahoo.com - September 16 at 11:19 AM
[video]Alder Biopharmaceuticals Surges on Lundbeck Offer[video]Alder Biopharmaceuticals Surges on Lundbeck Offer
finance.yahoo.com - September 16 at 11:19 AM
Alder (ALDR) Alert: Johnson Fistel Investigates Proposed Sale of Alder BioPharmaceuticals, Inc.; Are Shareholders Getting a Fair Deal?Alder (ALDR) Alert: Johnson Fistel Investigates Proposed Sale of Alder BioPharmaceuticals, Inc.; Are Shareholders Getting a Fair Deal?
finance.yahoo.com - September 16 at 11:19 AM
Alder BioPharmaceuticals stock rockets on heavy volume after $1.95 billion buyout dealAlder BioPharmaceuticals stock rockets on heavy volume after $1.95 billion buyout deal
finance.yahoo.com - September 16 at 11:19 AM
This Biotech Stock Just Rocketed 83% On A $2 Billion Takeover DealThis Biotech Stock Just Rocketed 83% On A $2 Billion Takeover Deal
finance.yahoo.com - September 16 at 11:19 AM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Alder BioPharmaceuticals, Inc. to H. Lundbeck A/S is Fair to ShareholdersSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Alder BioPharmaceuticals, Inc. to H. Lundbeck A/S is Fair to Shareholders
finance.yahoo.com - September 16 at 11:19 AM
Shareholder Alert: Ademi & OReilly, LLP Investigates whether Alder BioPharmaceuticals has obtained a Fair Price in its sale to H. Lundbeck A/SShareholder Alert: Ademi & O'Reilly, LLP Investigates whether Alder BioPharmaceuticals has obtained a Fair Price in its sale to H. Lundbeck A/S
finance.yahoo.com - September 16 at 11:19 AM
Bolt Biotherapeutics Appoints Veteran Executive Randall Schatzman as CEO to Lead the Next Phase of GrowthBolt Biotherapeutics Appoints Veteran Executive Randall Schatzman as CEO to Lead the Next Phase of Growth
finance.yahoo.com - September 4 at 9:52 AM
Alder BioPharmaceuticals(R) to Present at Two Upcoming September Investor ConferencesAlder BioPharmaceuticals(R) to Present at Two Upcoming September Investor Conferences
www.marketwatch.com - August 29 at 9:06 AM
Alder BioPharmaceuticals: Too Speculative, Too Many Competing Drugs In The Migraine MarketAlder BioPharmaceuticals: Too Speculative, Too Many Competing Drugs In The Migraine Market
seekingalpha.com - August 27 at 8:36 AM
Edited Transcript of ALDR earnings conference call or presentation 6-Aug-19 9:00pm GMTEdited Transcript of ALDR earnings conference call or presentation 6-Aug-19 9:00pm GMT
finance.yahoo.com - August 7 at 9:25 AM
Alder BioPharmaceuticals® Reports Second Quarter 2019 Financial and Operating ResultsAlder BioPharmaceuticals® Reports Second Quarter 2019 Financial and Operating Results
finance.yahoo.com - August 6 at 11:47 PM
Alder BioPharmaceuticals® to Present at Canaccord Genuity 39th Annual Growth ConferenceAlder BioPharmaceuticals® to Present at Canaccord Genuity 39th Annual Growth Conference
finance.yahoo.com - August 1 at 9:06 AM
Alder BioPharmaceuticals® to Host Conference Call to Discuss Second Quarter 2019 Financial and Operating ResultsAlder BioPharmaceuticals® to Host Conference Call to Discuss Second Quarter 2019 Financial and Operating Results
finance.yahoo.com - July 30 at 11:17 PM
Alder BioPharmaceuticals® Presents New Data on Migraine-Free Months, Migraine Severity and Quality of Life, Demonstrating Eptinezumab’s Clinical Profile for Migraine PreventionAlder BioPharmaceuticals® Presents New Data on Migraine-Free Months, Migraine Severity and Quality of Life, Demonstrating Eptinezumab’s Clinical Profile for Migraine Prevention
finance.yahoo.com - July 11 at 8:23 AM
Goldman likes HCA in premarket analyst actionGoldman likes HCA in premarket analyst action
seekingalpha.com - July 10 at 6:50 PM
Alder BioPharmaceuticals® to Showcase 14 New Data Presentations Demonstrating Eptinezumab’s Migraine Prevention and Quality of Life Impact at American Headache Society MeetingAlder BioPharmaceuticals® to Showcase 14 New Data Presentations Demonstrating Eptinezumab’s Migraine Prevention and Quality of Life Impact at American Headache Society Meeting
finance.yahoo.com - July 8 at 8:21 AM
All You Need to Know About Alder BioPharmaceuticals (ALDR) Rating Upgrade to BuyAll You Need to Know About Alder BioPharmaceuticals (ALDR) Rating Upgrade to Buy
finance.yahoo.com - July 3 at 6:52 PM
Alder BioPharmaceuticals® to Webcast Upcoming Breakfast Symposium with Key Opinion LeadersAlder BioPharmaceuticals® to Webcast Upcoming Breakfast Symposium with Key Opinion Leaders
finance.yahoo.com - June 19 at 8:44 AM
Alder BioPharmaceuticals® to Present at BMO Capital Markets 2019 Prescription for Success Healthcare ConferenceAlder BioPharmaceuticals® to Present at BMO Capital Markets 2019 Prescription for Success Healthcare Conference
finance.yahoo.com - June 18 at 4:21 PM
Imagine Owning Alder BioPharmaceuticals (NASDAQ:ALDR) While The Price Tanked 65%Imagine Owning Alder BioPharmaceuticals (NASDAQ:ALDR) While The Price Tanked 65%
finance.yahoo.com - June 4 at 6:47 PM
Alder BioPharmaceuticals® to Present at Two Upcoming May Investor ConferencesAlder BioPharmaceuticals® to Present at Two Upcoming May Investor Conferences
finance.yahoo.com - May 14 at 7:59 PM
Alders eptinezumab shows treatment effect in late-stage migraine studyAlder's eptinezumab shows treatment effect in late-stage migraine study
seekingalpha.com - May 8 at 7:36 PM
Alder BioPharmaceuticals® Presents New Analysis of Patient-Reported Outcomes Following Eptinezumab Treatment for Migraine PreventionAlder BioPharmaceuticals® Presents New Analysis of Patient-Reported Outcomes Following Eptinezumab Treatment for Migraine Prevention
www.globenewswire.com - May 8 at 8:24 AM
Geron's (GERN) Q1 Earnings Beat, Revenues Miss, Stock UpGeron's (GERN) Q1 Earnings Beat, Revenues Miss, Stock Up
finance.yahoo.com - May 6 at 7:39 PM
Alder BioPharmaceuticals® Presents New Data Demonstrating Consistent, Early and Robust Prevention with Eptinezumab for Episodic and Chronic Migraine across Four Clinical TrialsAlder BioPharmaceuticals® Presents New Data Demonstrating Consistent, Early and Robust Prevention with Eptinezumab for Episodic and Chronic Migraine across Four Clinical Trials
finance.yahoo.com - May 6 at 8:23 AM
Edited Transcript of ALDR earnings conference call or presentation 2-May-19 9:00pm GMTEdited Transcript of ALDR earnings conference call or presentation 2-May-19 9:00pm GMT
finance.yahoo.com - May 3 at 7:13 PM
Bob Azelby awaits approval of Alder’s migraine drugBob Azelby awaits approval of Alder’s migraine drug
finance.yahoo.com - May 3 at 7:13 PM
Alder BioPharmaceuticals, Inc. (ALDR) Q1 2019 Earnings Call TranscriptAlder BioPharmaceuticals, Inc. (ALDR) Q1 2019 Earnings Call Transcript
finance.yahoo.com - May 3 at 8:28 AM
Alder BioPharmaceuticals® Reports First Quarter 2019 Financial and Operating ResultsAlder BioPharmaceuticals® Reports First Quarter 2019 Financial and Operating Results
www.globenewswire.com - May 2 at 7:59 PM
Analysts point to potential Biogen M&A options after Alzheimer's failureAnalysts point to potential Biogen M&A options after Alzheimer's failure
finance.yahoo.com - April 26 at 8:25 AM
Why This Migraine-Focused Biotech Stock Could Be The Next TakeoverWhy This Migraine-Focused Biotech Stock Could Be The Next Takeover
finance.yahoo.com - April 23 at 6:31 PM
Alder BioPharmaceuticals® to Present New Analyses of Eptinezumab’s Clinical Trial Data Describing Early, Robust Migraine Prevention and Quality of Life Impact at 2019 American Academy of Neurology Annual MeetingAlder BioPharmaceuticals® to Present New Analyses of Eptinezumab’s Clinical Trial Data Describing Early, Robust Migraine Prevention and Quality of Life Impact at 2019 American Academy of Neurology Annual Meeting
finance.yahoo.com - April 23 at 8:16 AM
FDA accepts Alders application for eptinezumabFDA accepts Alder's application for eptinezumab
seekingalpha.com - April 22 at 6:21 PM
U.S. Food and Drug Administration Accepts Biologics License Application for EptinezumabU.S. Food and Drug Administration Accepts Biologics License Application for Eptinezumab
finance.yahoo.com - April 22 at 6:21 PM
Alder Biopharmaceuticals CEO: Spreading migraine awarenessAlder Biopharmaceuticals CEO: Spreading migraine awareness
finance.yahoo.com - April 5 at 7:48 PM
Alder BioPharmaceuticals® to Present at the 18th Annual Needham Healthcare ConferenceAlder BioPharmaceuticals® to Present at the 18th Annual Needham Healthcare Conference
finance.yahoo.com - April 2 at 8:42 AM
This page was last updated on 2/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel